52 Stocks Moving In Monday's Mid-Day Session

Author: Lisa Levin | December 14, 2020 01:02pm

Gainers

• Arvinas, Inc. (NASDAQ:ARVN) shares jumped 103.4% to $60.87 after the company reported interim clinical data for its cancer treatment. The company said ARV-471 showed evidence of anti-tumor activity.
• AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC) gained 78.2% to $7.52 after the company said it made significant progress in detecting pre-cancer diseases.
• Teligent, Inc. (NASDAQ:TLGT) jumped 64.8% to $1.0389 after declining over 8% on Friday. A Special Meeting of Stockholders is scheduled to reconvene on Wednesday December 16.
• Veru Inc. (NASDAQ:VERU) shares climbed 60% to $10.17. Veru reported Phase 2 trial results for enobosarm for endocrine resistant metastatic breast cancer.
• Rubius Therapeutics, Inc. (NASDAQ:RUBY) gained 45.9% to $9.32 after declining around 17% on Friday.
• Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares jumped 30.4% to $157.71 after AstraZeneca plc (NASDAQ:AZN) announced plans buy the company for $39 billion.
• Recro Pharma, Inc. (NASDAQ:REPH) gained 30.2% to $3.85 after climbing around 37% on Friday.
• BioCardia, Inc. (NASDAQ:BCDA) shares rose 30.1% to $3.70. BioCardia said it expects data safety monitoring board verbal feedback for interim data from Phase 3 CardiaAMP heart failure trial by the end of December 15, 2020.
• Evelo Biosciences, Inc. (NASDAQ:EVLO) surged 29.3% to $9.75 after jumping around 18% on Friday. Evelo Biosciences, last week, reported new clinical candidate in oncology.
• Atomera Incorporated (NASDAQ:ATOM) surged 21.4% to $13.14.
• Marathon Patent Group, Inc. (NASDAQ:MARA) shares gained 19.6% to $5.68 after declining 9% on Friday. HC Wainwright & Co maintained a Buy rating on the stock and raised its price target from $7.5 to $9. Marathon Patent Group last week purchased additional 10K S-19j Pro ASIC miners from Bitmain and announced plans to open a second data center.
• DermTech, Inc. (NASDAQ:DMTK) shares surged 19.4% to $13.72. DermTech, on Friday, announced Inclusion of its melanoma test in two continuing medical education sessions at 2020 Fall Clinical Virtual Grand Rounds and Mount Sinai Winter Symposium.
• Alimera Sciences, Inc. (NASDAQ:ALIM) gained 19% to $4.9747. Alimera Sciences, last week, reported the launch of ILUVIEN in The Netherlands.
• 22nd Century Group, Inc. (NYSE:XXII) surged 18.8% to $3.02 after climbing 18% on Friday.
• Homology Medicines, Inc. (NASDAQ:FIXX) rose 18.2% to $12.10.
• Synlogic Inc (NASDAQ:SYBX) shares gained 17.4% to $2.63 after the company announced plans to advance its cancer treatment into the combination therapy stage of its phase 1 trial.
• Gatos Silver, Inc. (NYSE:GATO) shares rose 16.6% to $8.77. Gatos Silver reported quarterly results last week.
• Aligos Therapeutics, Inc. (NASDAQ:ALGS) gained 16.5% to $25.76.
• ReneSola Ltd (NYSE:SOL) shares rose 16.4% to $6.45. HC Wainwright & Co. maintained ReneSola with a Buy and raised the price target from $4 to $12.
• LogicBio Therapeutics, Inc. (NASDAQ:LOGC) surged 15.8% to $8.88.
• Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) shares rose 15.4% to $11.71.
• Inseego Corp. (NASDAQ:INSG) gained 15.4% to $15.87 after climbing 12% on Friday. The company on Thursday announced its 5G MiFi M2000 mobile hotspot is now available at T-Mobile and on Friday announced the availability of 5G MiFi M200 in Japan.
• Chinook Therapeutics, Inc. (NASDAQ:KDNY) surged 14.9% to $15.31. Chinook Therapeutics reported a license agreement with Morehouse School of Medicine for development of therapies in kidney diseases disproportionately affecting African Americans and underserved communities.
• Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) rose 14.7% to $54.88. Apellis and Sobi last week reported top-lone results at 48 weeks from Phase 3 PEGASUS study of pegcetacoplan in PNH.
• Prevail Therapeutics Inc. (NASDAQ:PRVL) jumped 14.3% to $13.36. Prevail Therapeutics, last week, said first patient was dosed in Phase 1/2 PROCLAIM trial evaluating PR006 for the treatment of frontotemporal dementia patients with GRN mutations.
• Nurix Therapeutics, Inc. (NASDAQ:NRIX) shares surged 14% to $45.30.
• C4 Therapeutics, Inc. (NASDAQ:CCCC) gained 13.8% to $33.03.
• Summit Wireless Technologies, Inc. (NASDAQ:WISA) surged 13.7% to $2.97 after HC Wainwright & Co initiated coverage on the stock with a Buy rating and announced a $3.5 price target.
• Socket Mobile, Inc. (NASDAQ:SCKT) climbed 13.6% to $3.0225 after the company announced it received a notice of forgiveness from Western Alliance Bank for the $1.06 million PPP loan.
• GoHealth, Inc. (NASDAQ:GOCO) surged 12% to $14.88.
• Riot Blockchain, Inc. (NASDAQ:RIOT) rose 10.6% to $9.58 after declining 7% on Friday.
• Amarin Corporation plc (NASDAQ:AMRN) rose 6.2% to $5.32 after the company said VACEPA Covid-19 Cardiolink-9 randomized trial suggests improvement in outpatient-reported Covid-19 symptoms.
• Pluralsight, Inc. (NASDAQ:PS) rose 6% to $20.10 after the company agreed to be acquired by private-equity firm Vista Equity Partners in an all-cash transaction for $20.26 per share..

Check out these big penny stock gainers and losers

Losers

• Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO) shares dipped 46.9% to $1.1950 after the company disclosed results from its phase 2 trial of Razuprotafib glaucoma. HC Wainwright & Co. maintained Aerpio Pharmaceuticals with a Neutral and lowered the price target from $2 to $1.5.
• Greenwich LifeSciences, Inc. (NASDAQ:GLSI) dropped 26.4% to $41.24 after declining over 22% on Friday. Greenwich LifeSciences last week shared the poster for the GP2 Phase 2b clinical trial final efficacy analysis that was presented Wednesday at the 2020 San Antonio Breast Cancer Symposium.
• SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) fell 24% to $6.36. SELLAS Life Sciences Group shares tumbled around 53% on Friday after the company reported follow-up data from a randomized Phase 2 VADIS trial of Nelipepimut-S in woman with ductal carcinoma in-situ of the breast.
• Destination XL Group, Inc. (NASDAQ:DXLG) fell 23.8% to $0.2397 after the company announced it would delist from the Nasdaq.
• TechTarget, Inc. (NASDAQ:TTGT) dropped 16.8% to $50.08 after the company reported a proposed offering of convertible senior notes.
• Gamida Cell Ltd (NASDAQ:GMDA) shares declined 15.8% to $8.36 after the company pushed back its timeline to submit a biologics license application from 2020 to 2H 2021 due to additional data requests from the Food and Drug Administration.
• NextDecade Corporation (NASDAQ:NEXT) dipped 15.7% to $2.91 after climbing 38% on Friday.
• SolarWinds Corporation (NYSE:SWI) fell 15% to $20.00 after the company said some of its products may have been affected by a highly sophisticated hack.
• AMC Entertainment Holdings, Inc. (NYSE:AMC) dropped 14.8% to $3.34.
• Fusion Fuel Green PLC (NASDAQ:HTOO) fell 14.6% to $16.82.
• Vivos Therapeutics, Inc. (NASDAQ:VVOS) shares fell 12.8% to $7.84. Vivos Therapeutics shares climbed around 50% on Friday after the company priced its IPO at $6 per share..
• Immutep Limited (NASDAQ:IMMP) fell 12.7% to $3.0450 after declining over 38% on Friday. Immutep last week reported a statistically significant survival benefit for key patient groups in its ongoing Phase IIb AIPAC study in metastatic breast cancer.
• Xenetic Biosciences, Inc. (NASDAQ:XBIO) fell 12.7% to $1.99. Xenetic Biosciences, last week, announced a roughly 2.45 million shares registered direct offering priced at $2.45 per share.
• Fossil Group, Inc. (NASDAQ:FOSL) dropped 12.1% to $11.68.
• Team, Inc. (NYSE:TISI) fell 11.6% to $9.82.
• Virgin Galactic Holdings, Inc. (NASDAQ:SPCE) shares fell 11.1% to $28.47. A test flight of the VSS Unity from Virgin Galactic returned home early after an ignition failure on Saturday.
• NantHealth, Inc. (NASDAQ:NH) dropped 10.5% to $3.08. NantHealth recently presented significant treatment insights at the 2020 San Antonio Breast Cancer Symposium in a time of need with the pandemic’s impact on cancer care.
• Neos Therapeutics, Inc. (NASDAQ:NEOS) fell 8.2% to $0.6350. Neos Therapeutics and Aytu Biosciences last week announced a merger agreement.
• AstraZeneca PLC (NYSE:AZN) fell 6.8% to $50.60 after the company announced it would acquire Alexion Pharmaceuticals for $39 billion in cash and stock.

Posted In: ALGS ALIM ALXN AMC AMRN ANPC APLS ARPO ARVN ATOM AZN BCDA CCCC DMTK DXLG EVLO FIXX FOSL GATO GLSI